NitroMed, Inc. (NASDAQ: NTMD) today announced that Kenneth M. Bate, the Company’s President and Chief Executive Officer, will present a corporate update at Thomas Weisel Partners’ Annual Healthcare Conference, being held at the Four Seasons Boston from September 5 through September 7, 2007. NitroMed’s presentation is scheduled for Thursday, September 6, at 10:55 am (ET). The 30-minute presentation, which includes an interactive discussion with attending analysts and investors, will be webcast and accessible on NitroMed’s website (www.nitromed.com) for a limited period of time following the conference.
About NitroMed, Inc.
NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as angiotensin converting enzyme (ACE) inhibitors and beta blockers. There is little experience in patients with New York Heart Association Class IV heart failure. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company's landmark A-HeFT (African American Heart Failure Trial) clinical trial and is marketed by NitroMed through a specialty medicines sales organization.
For full prescribing information, visit: www.BiDil.com. BiDil is a registered trademark of NitroMed, Inc.